LIFECORE BIOMEDICAL, INC. DE (LFCR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 05-25. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 200M 400M 600M FY10: 238.2M FY11: 276.7M FY12: 317.6M FY13: 441.7M FY14: 476.8M FY15: 539.3M FY16: 476.9M FY17: 469.8M FY18: 524.2M FY19: 557.6M FY20: 160.1M FY21: 100.9M FY22: 111.3M FY23: 103.3M FY24: 128.3M FY25: 128.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 30M 60M 90M FY10: 33.8M FY11: 46.7M FY12: 52.1M FY13: 62.8M FY14: 62.6M FY15: 65.4M FY16: 66.8M FY17: 79.2M FY18: 78.3M FY19: 81M FY20: 39.4M FY21: 38.9M FY22: 39.1M FY23: 28M FY24: 41.9M FY25: 40.3M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-27M -18M -9M 0 9M 18M 27M FY10: 8M FY11: 8M FY12: 14.6M FY13: 24.9M FY14: 20.2M FY15: 18.5M FY16: -20.6M FY17: 14.7M FY18: 13.6M FY19: 5.5M FY20: -25.9M FY21: -8.8M FY22: -11.8M FY23: -21.8M FY24: -8.8M FY25: -17.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-120M -80M -40M 0 40M 80M 120M FY10: 4M FY11: 3.9M FY12: 12.7M FY13: 22.6M FY14: 19.1M FY15: 13.5M FY16: -11.6M FY17: 10.6M FY18: 24.8M FY19: 411K FY20: -38.2M FY21: -32.3M FY22: -116.7M FY23: -99.6M FY24: 12M FY25: -38.7M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 200M 400M 600M FY10: 204.5M FY11: 230M FY12: 265.4M FY13: 378.9M FY16: 410.1M FY17: 390.6M FY18: 445.9M FY19: 476.6M FY20: 120.7M FY21: 61.9M FY22: 72.2M FY23: 75.3M FY24: 86.4M FY25: 88.6M FY11 FY13 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-30M -15M 0 15M 30M 45M FY10: 7.5M FY11: 14.5M FY12: 22.2M FY13: 21.2M FY14: 21M FY15: 26.6M FY16: 20.8M FY17: 29.8M FY18: 19.8M FY19: 16M FY20: -17M FY21: 16.5M FY22: -22.6M FY23: -17.4M FY24: 257K FY25: -206K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY10: 2.3M FY11: 7.8M FY12: 16.8M FY13: 12.4M FY14: 6.2M FY15: 9.1M FY16: -18.9M FY17: 6.8M FY18: -13.8M FY19: -28.7M FY20: -29.3M FY21: -2.8M FY22: -48.8M FY24: -18.1M FY25: -13.6M FY10 FY12 FY14 FY16 FY18 FY20 FY22 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY10: 26.6K FY11: 26.6M FY12: 26.1M FY13: 26.6K FY14: 27.1M FY15: 27.3M FY16: 27M FY17: 27.7M FY18: 27.9M FY19: 28.6M FY20: 29.2M FY21: 29.3M FY22: 29.5M FY23: 30M FY24: 36.7M FY25: 34.8M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q2 '13: 0.80 Q3 '13: 0.80 Q4 '13: 0.86 Q1 '14: 0.87 Q2 '14: 0.66 Q3 '14: 0.72 Q4 '14: 0.72 Q1 '15: 0.63 Q4 '15: 0.50 Q1 '16: 0.52 Q2 '16: 0.47 Q3 '16: -0.45 Q4 '16: -0.43 Q1 '17: -0.42 Q2 '17: -0.44 Q3 '17: 0.47 Q4 '17: 0.39 Q1 '18: 0.35 Q2 '18: 0.32 Q3 '18: 0.76 Q4 '18: 0.89 Q1 '19: 0.82 Q2 '19: 0.78 Q3 '19: 0.25 Q4 '19: 0.01 Q1 '20: -0.16 Q2 '20: -0.37 Q3 '20: -0.80 Q4 '20: -1.30 Q1 '21: -1.52 Q2 '21: -1.74 Q3 '21: -1.54 Q4 '21: -1.06 Q1 '22: -1.00 Q2 '22: -1.85 Q3 '22: -2.11 Q4 '22: -3.95 Q1 '23: -4.00 Q2 '23: -3.13 Q3 '23: -3.88 Q4 '23: -3.32 Q1 '24: -3.30 Q2 '24: -2.48 Q3 '24: -0.86 Q4 '24: 0.33 Q1 '25: 0.15 Q2 '25: -0.49 Q3 '25: -1.33 Q4 '25: -1.26 Q4 '14 Q1 '17 Q4 '18 Q3 '20 Q2 '22 Q1 '24 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.